Ballast Inc. raised its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,913 shares of the company’s stock after buying an additional 108 shares during the quarter. Ballast Inc.’s holdings in Eli Lilly And Co were worth $645,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Voya Financial Advisors Inc. boosted its holdings in shares of Eli Lilly And Co by 14.4% in the 3rd quarter. Voya Financial Advisors Inc. now owns 13,059 shares of the company’s stock worth $1,467,000 after purchasing an additional 1,640 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Eli Lilly And Co by 5.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,285 shares of the company’s stock worth $479,000 after purchasing an additional 233 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Eli Lilly And Co by 13.9% in the 2nd quarter. Assetmark Inc. now owns 410,334 shares of the company’s stock worth $45,461,000 after purchasing an additional 50,087 shares in the last quarter. Norway Savings Bank boosted its holdings in shares of Eli Lilly And Co by 8.7% in the 3rd quarter. Norway Savings Bank now owns 6,912 shares of the company’s stock worth $773,000 after purchasing an additional 555 shares in the last quarter. Finally, Integrated Wealth Concepts LLC boosted its holdings in shares of Eli Lilly And Co by 4.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 4,108 shares of the company’s stock worth $459,000 after purchasing an additional 174 shares in the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.

Shares of NYSE:LLY traded up $0.16 during trading on Tuesday, hitting $139.10. The stock had a trading volume of 1,012,729 shares, compared to its average volume of 3,244,057. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $139.99. The company has a market capitalization of $132.50 billion, a PE ratio of 25.06, a PEG ratio of 1.80 and a beta of 0.20. The firm’s fifty day moving average is $126.70 and its 200 day moving average is $115.12. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The firm had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the prior year, the company earned $1.39 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Equities research analysts expect that Eli Lilly And Co will post 5.8 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be given a $0.74 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.96 annualized dividend and a dividend yield of 2.13%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.

A number of equities analysts have recently issued reports on LLY shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a report on Monday, December 2nd. JPMorgan Chase & Co. upped their price objective on Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Bank of America started coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Finally, Morgan Stanley upgraded Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $135.67.

In related news, SVP Anne E. White purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were bought at an average price of $108.84 per share, for a total transaction of $108,840.00. Following the purchase, the senior vice president now directly owns 22,043 shares of the company’s stock, valued at approximately $2,399,160.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jackson P. Tai purchased 1,861 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was bought at an average price of $107.49 per share, for a total transaction of $200,038.89. Following the purchase, the director now directly owns 56,440 shares in the company, valued at $6,066,735.60. The disclosure for this purchase can be found here. In the last three months, insiders bought 8,405 shares of company stock valued at $909,004 and sold 1,575,504 shares valued at $191,219,312. 0.11% of the stock is currently owned by corporate insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What is the float in trading stocks?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.